文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

大环内酯耐药肺炎支原体感染在儿童社区获得性肺炎中的影响

Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia.
PubMed 文献 · Emerg Infect Dis · 2020-01-01

该系统综述与荟萃分析探讨大环内酯耐药对肺炎支原体感染临床表现及临床判断的影响。研究发现耐药与敏感菌株感染在临床严重程度上无差异,但耐药感染发热期、住院时间、抗生素疗程及退热时间均延长,且大环内酯治疗后发热持续>48小时风险及更换二线治疗比例显著增加。

要点

  • 耐药与敏感菌株感染的临床严重程度无差异。
  • 耐药感染发热期延长1.71天,住院时间延长1.61天。
  • 耐药感染大环内酯治疗后发热持续>48小时风险OR为21.24。

核心结论

  • 大环内酯耐药与敏感肺炎支原体感染在临床严重程度上无差异。
  • 耐药感染导致发热期、住院时间、抗生素疗程及退热时间延长。
  • 耐药感染增加大环内酯治疗后发热持续>48小时风险及更换二线治疗比例。

研究设计与样本

  • 系统综述与荟萃分析,研究对象为肺炎支原体感染患者。

主要发现

  • 耐药与敏感感染临床严重程度无差异。
  • 耐药感染发热期延长1.71天。
  • 耐药感染住院时间延长1.61天。
  • 耐药感染抗生素疗程延长2.93天。
  • 耐药感染大环内酯治疗后退热时间延长2.04天。

关键数值与推荐

  • 大环内酯治疗后发热持续>48小时的OR为21.24。
  • 更换二线治疗的OR为4.42。

临床怎么用

  • 对大环内酯耐药肺炎支原体感染需考虑诊断与治疗挑战。
  • 未来需评估更精确的诊断工具和明确治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A high prevalence rate of macrolide-resistant Mycoplasma pneumoniae (MRMP) has been reported in Asia. We performed a systematic review and meta-analysis to investigate the effect of macrolide resistance on the manifestations and clinical judgment during M. pneumoniae infections. We found no difference in clinical severity between MRMP and macrolide-sensitive Mycoplasma pneumoniae (MSMP) infections. However, in the pooled data, patients infected with MRMP had a longer febrile period (1.71 days), length of hospital stay (1.61 day), antibiotic drug courses (2.93 days), and defervescence time after macrolide treatment (2.04 days) compared with patients infected with MSMP. The risk of fever lasting for >48 hours after macrolide treatment was also significantly increased (OR 21.24), and an increased proportion of patients was changed to second-line treatment (OR 4.42). Our findings indicate diagnostic and therapeutic challenges after the emergence of MRMP. More precise diagnostic tools and clearly defined treatment should be appraised in the future.

来源:Emerg Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chen YC, Hsu WY, Chang TH, et al. Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia. Emerg Infect Dis. 2020. PMID: 32568052. doi:10.3201/eid2607.200017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。